Press coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.9027218557216 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Merrimack Pharmaceuticals (MACK) opened at $11.86 on Tuesday. The company has a current ratio of 3.35, a quick ratio of 3.35 and a debt-to-equity ratio of 0.45. Merrimack Pharmaceuticals has a fifty-two week low of $11.14 and a fifty-two week high of $67.90.

Several research firms recently weighed in on MACK. Robert W. Baird restated a “hold” rating and issued a $15.00 price objective on shares of Merrimack Pharmaceuticals in a report on Friday, October 13th. Zacks Investment Research downgraded Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, ValuEngine upgraded Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a strong buy rating to the stock. Merrimack Pharmaceuticals presently has an average rating of “Hold” and an average price target of $61.80.

TRADEMARK VIOLATION WARNING: “Merrimack Pharmaceuticals (MACK) Getting Somewhat Favorable Media Coverage, Study Shows” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/merrimack-pharmaceuticals-mack-getting-somewhat-favorable-media-coverage-study-shows/1701395.html.

In other Merrimack Pharmaceuticals news, Director Ulrik B. Nielsen sold 7,896 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $14.23, for a total value of $112,360.08. Following the completion of the transaction, the director now directly owns 22,781 shares in the company, valued at $324,173.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ulrik B. Nielsen sold 14,756 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $14.46, for a total transaction of $213,371.76. Following the completion of the transaction, the director now owns 37,437 shares of the company’s stock, valued at $541,339.02. The disclosure for this sale can be found here. Insiders sold 44,308 shares of company stock valued at $637,558 over the last quarter. 8.53% of the stock is currently owned by corporate insiders.

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.